Stockscreener 앱 받기
4.58
1.72%
-0.08
전일 마감가:
$4.66
열려 있는:
$4.53
하루 거래량:
986.21K
Relative Volume:
1.14
시가총액:
$325.86M
수익:
$14.20M
순이익/손실:
$-49.59M
주가수익비율:
-5.4368
EPS:
-0.8424
순현금흐름:
$-35.25M
1주 성능:
-5.37%
1개월 성능:
+28.29%
6개월 성능:
+201.32%
1년 성능:
+298.26%
1일 변동 폭
$4.33
$4.64
1주일 범위
$4.33
$5.28
52주 변동 폭
$0.65
$5.30
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.58 | 325.86M | 14.20M | -49.59M | -35.25M | -0.8424 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 116.36B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 77.96B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.36B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | Oppenheimer | Outperform |
| 2026-01-20 | 개시 | BTIG Research | Buy |
| 2025-12-10 | 개시 | B. Riley Securities | Buy |
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2025-10-29 | 개시 | Wedbush | Outperform |
| 2025-10-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-11 | 개시 | Craig Hallum | Buy |
| 2024-11-13 | 재개 | H.C. Wainwright | Buy |
모두보기
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Opus Genetics, Inc. (IRD) reports Q4 loss, tops revenue estimates - MSN
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells 2,816 Shares of Stock - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells $19,041.28 in Stock - MarketBeat
Opus Genetics COO Schachle sells $19,525 in stock By Investing.com - Investing.com South Africa
Opus Genetics COO Schachle sells $19,525 in stock - Investing.com
Insider Selling: Opus Genetics (NASDAQ:IRD) CEO Sells 24,438 Shares of Stock - MarketBeat
Opus Genetics chief scientific officer sells $19k in stock - Investing.com
Opus Genetics (IRD) officer has 2,816 shares sold to cover tax - Stock Titan
Opus Genetics (IRD) CEO has shares sold automatically to cover RSU taxes - Stock Titan
Opus Genetics (IRD) CSO has shares sold automatically for tax withholding - Stock Titan
Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN
Aug Catalysts: Can Opus Genetics Inc reach all time highs this yearMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Oppenheimer initiates coverage of Opus Genetics (IRD) with outperform recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Up 17.9% in February - MarketBeat
Opus Genetics (IRD) Initiates Coverage with Outperform Rating by Oppenheimer | IRD Stock News - GuruFocus
Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD) - MarketBeat
Oppenheimer Analyst Initiates Coverage on Opus Genetics (IRD) wi - GuruFocus
Oppenheimer Initiates Opus Genetics at Outperform With $10 Price Target - marketscreener.com
There's Reason For Concern Over Opus Genetics, Inc.'s (NASDAQ:IRD) Massive 26% Price Jump - 富途牛牛
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Biotechnology company Opus Genetics Inc recently filed documents with the U.S. Securities and Exchange Commission (SEC) to officially register 7.4 million shares of common stock for secondary market resale. - Bitget
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
HC Wainwright Has Negative View of Opus Genetics Q1 Earnings - MarketBeat
Lifesci Capital Forecasts Lower Earnings for Opus Genetics - MarketBeat
BTIG raises its price target on Opus Genetics, Inc. (IRD) to $12 from $7 and maintains a buy rating - MSN
Opus Genetics, Inc. 2025 Annual Report: Gene Therapy Pipeline, Clinical Progress, and Strategic Partnerships in Ophthalmology - Minichart
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch - TipRanks
Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD) - The Globe and Mail
Opus Genetics (NASDAQ:IRD) Given New $10.00 Price Target at Wedbush - MarketBeat
Opus Genetics (NASDAQ:IRD) Stock Price Expected to Rise, Chardan Capital Analyst Says - MarketBeat
Opus Genetics (IRD) Target Price Raised by Wedbush Analyst | IRD Stock News - GuruFocus
Chardan Capital Raises Price Target for Opus Genetics (IRD) to $11 | IRD Stock News - GuruFocus
Opus Genetics (IRD) Gets a Buy from H.C. Wainwright - The Globe and Mail
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating - Insider Monkey
IRD Technical Analysis | Trend, Signals & Chart Patterns | OPUS GENETICS INC (NASDAQ:IRD) - ChartMill
Craig-Hallum Maintains Buy on Opus Genetics (IRD) March 2026 - Meyka
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA) - The Globe and Mail
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target By Investing.com - Investing.com India
Craig-Hallum reiterates Buy on Opus Genetics stock, $9 target - Investing.com South Africa
Opus Genetics (IRD) Trailing US$49.6m Loss Reinforces Bearish Profitability Narrative - Sahm
Opus Genetics Inc. (IRD) Reports FY25 Earnings - AlphaStreet
Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M - AlphaStreet
Opus Genetics, Inc. (IRD) Announces Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Opus Genetics (IRD) Exceeds Revenue Projections and Advances Gen - GuruFocus
Earnings Summary: Opus Genetics Q4 - Benzinga
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update - The Manila Times
Craig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - MSN
Opus Genetics (IRD) Price Target Increased by 13.45% to 7.87 - MSN
Is Opus Genetics Inc. stock near bottom after declineQuarterly Growth Report & Smart Swing Trading Alerts - Naître et grandir
Market Recap: Can Opus Genetics Inc benefit from deglobalizationQuarterly Investment Review & Stock Portfolio Risk Control - baoquankhu1.vn
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):